Analysis of the pricing situation of the Indian version of Apelix

Alpelisib (Alpelisib) is a targeted therapy for certain types of breast cancer. It is suitable for patients with locally advanced or metastatic breast cancer who are hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) and have specific mutations in the PIK3CA gene. In these patients, mutations in the PIK3CA gene lead to abnormal activation of the PI3K enzyme, which in turn stimulates the disordered proliferation of cancer cells. Apelvis slows the growth and spread of cancer cells by inhibiting this abnormally activated PI3K enzyme.

When hormone therapy is no longer effective, apelvis is often used in combination with fuvestrant to provide additional therapeutic benefit. However, the high price of original drugs often becomes an obstacle for patients to obtain effective treatment. Therefore, there is an increasing demand for more affordable generic drugs in the market.

As a world-renowned major producer of generic drugs, India has rich experience and technology accumulation in drug R&D and production. However, as of April 2024, there is no news of the Indian version of Apelvis generic being put on the market. Currently, the only generic Apelvis drug on the market comes from Lucius Pharmaceuticals in Laos. Its specification is 150mg*28 tablets/box, and the price is about more than 2,000 yuan, which may change due to exchange rate fluctuations. Despite this, this price still has significant advantages over the original drug, providing patients with a more economical treatment option.

It should be noted that although generic drugs are similar to original drugs in terms of active ingredients, dosage forms, routes of administration and therapeutic effects, there may be differences in production processes, quality control and excipient selection. Therefore, when using generic drugs, patients should follow their doctor's recommendations and pay close attention to their efficacy and safety.